Amrad forecasts profit, acquisitions
02 July, 2003 by Jeremy TorrAmrad’s bulging coffers and a good prognosis have helped it forecast an overall profit for the year to June 2003, according to latest figures from the company.
Virax brings in Clearview
02 July, 2003 by Melissa TrudingerMelbourne company Virax (ASX: VHL) introduced shareholders to its strategy for partnering in a video conference with US bio-partnering specialists Clearview Projects yesterday, in a move designed to raise shareholder awareness of the partnering process and its importance to biotechnology companies.
Starpharma gets gel trial nod
02 July, 2003 by Jeremy TorrDendrimer nanotechnology company Starpharma has submitted an Investigational New Drug (IND) application to the FDA for Phase I clinical trials on its SPL7013 vaginal microbicide gel.
InterSuisse backs tanning drug
01 July, 2003 by Jeremy TorrMelbourne-based biotech EpiTan has sealed a deal with stockbroking firm Intersuisse Corporate Pty Ltd to underwrite $2,500,000 worth of shares in the company.
Iliad scores drug discovery funding
01 July, 2003 by Jeremy TorrANU spin off Iliad Chemicals has gained $2million worth of research funding from life sciences VC Start-up Australia Ventures Pty. The money will be ploughed into investigation of complex molecule technology as an anti-cancer agent.
Local biotech stocks surging
01 July, 2003 by Jeremy TorrLatest good news from the finance market comes in a report from market analysts, Bioshares. The report rates Australian biotech stocks as ‘surging ahead in the June quarter’ with an over 20 per cent rise across a basket of 43 sampled stocks.
AGT competes in global arena
30 June, 2003 by Melissa TrudingerThe publication of a paper on the three dimensional structure of a protein discovered and patented by Victorian company AGT Biosciences by scientists at a major pharmaceutical company last week was a wake-up call that AGT was competitive in the global arena, CEO Prof Greg Collier told Australian Biotechnology News today.
AgGenomics in JV with Horticulture Australia
26 June, 2003 by Melissa TrudingerAgGenomics, a joint venture between Genetic Technologies and the Victorian State Government's Agriculture Victoria Services, has entered into a two year collaborative program with Horticulture Australia to identify genetic markers in strawberries.
IMB genetics professor tops world list
25 June, 2003 by Jeremy TorrProfessor Wayne Hall of the Queensland-based Institute for Molecular Bioscience (IMB) has been named as one of the most published authors in his field - the genetics of addiction and mental disorders.
A bookmark in history
24 June, 2003 by Jeremy TorrSteve Burrill, long time money man for the IT and biotech industries, visited Australia last week to raise $200million for a new biotech fund. He described this decade as being of such importance that it will be remembered in 1000 years' time. ABN met with him, and asked why. Jeremy Torr reports.
Sigma to buy Pan?
23 June, 2003 by Jeremy TorrConsumable and mining chemical company Sigma is reported as being latest in the queue to buy TGA-smitten Pan Pharmaceuticals. Other bidders are believed to include API and major Pan creditor Mayne
Amrad in research collaboration with Merck Sharp & Dohme
23 June, 2003 by Melissa TrudingerMelbourne biotechnology company Amrad has formed a research collaboration with Merck Sharp & Dohme (MSD) with a total worth of $US112 million plus royalties to develop therapeutic drugs for asthma, respiratory diseases and cancer, the company announced today at the BIO2003 conference in Washington DC.
OGTR stops clock on GM canola
20 June, 2003 by Melissa TrudingerThe OGTR has stopped the clock for a second time on Bayer CropScience's application for commercial release of its InVigor genetically modified canola.
PsiMedica enters revenue sharing agreement
19 June, 2003 by Melissa TrudingerPerth nanotechnology company PsiVida announced that its British subsidiary PsiMedica has entered into a revenue sharing agreement with Texas Christian University (TCU) over an invention with applications in orthopaedics and tissue engineering.
Bio Pharma signs $3.5m contract
18 June, 2003 by Pete YoungA $3.5 million dollar conditional contract with an Asian company could give startup Bio Pharma Pty Ltd the push it needs to move into commercial production.
